Boston, MA 07\/15\/2014 (wallstreetpr) \u2013 Pfizer Inc. (NYSE:PFE)<\/b> has been a subject of a number of analysts on Wall Street, especially since its failed bid for AstraZeneca plc (ADR) (NYSE:AZN)<\/b>. Sentiments on the stock have also been based on its aging products, especially Lipitor that has become a shell of its former self. Some analysts have also based their sentiments on the company\u2019s product pipeline.<\/p>\n
According to analysts at Jefferies Group, the latest rating firm to comment on the stock of Pfizer, the company is a Buy. The firm also upgraded their price target on the stock from $36 to $38. The new price target suggests about 26 percent premium over the prevailing prices.<\/p>\n
Other analysts rating firms that have recently weighed in on the stock of Pfizer Inc. (NYSE:PFE) include Barclays, which have an Equal-weight rating and raised their price target on the stock to $34 from $32. Analysts at JPMorgan Chase & Co. (NYSE:JPM)<\/b> rate the stock an Overweight with a price target of $35. At Zacks, the stock carries a Neutral rating and a price target of $31.<\/p>\n
Out of the 15 analysts covering the stock, nine have it on a Buy list while six recommend a Hold. That gives Pfizer Inc. (NYSE:PFE) a consensus Buy rating and an average price target of $33.97.<\/p>\n
Fresh bid for AstraZeneca<\/strong><\/p>\n Pfizer Inc. (NYSE:PFE)\u2019s favorable rating is because of the chances of the company to reinvent itself. Analysts still believe that the company could soon make another bid for AstraZeneca, a move that will help it to boost revenue and reincorporate outside the U.S. so as to enjoy lower corporate taxes.<\/p>\n Rich pipeline<\/b><\/p>\n Of all the promises in the Pfizer, nothing is more compelling than its product pipeline.\u00a0Pfizer Inc. (NYSE:PFE) has a rich pipeline, in fact, one of the best in the industry, which could be a game-changer in the few years. That should be a good reason for investors to be patient with the company even though its bestselling products have been exposed to generic competition because of the loss of market exclusivity.<\/p>\n","protected":false},"excerpt":{"rendered":" Boston, MA 07\/15\/2014 (wallstreetpr) \u2013 Pfizer Inc. (NYSE:PFE) has been a subject of a number of analysts on Wall Street, especially since its failed bid […]<\/p>\n","protected":false},"author":9,"featured_media":22248,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236,264],"tags":[4503,1628,4504,603,993,2745],"stock_ticker":[],"class_list":["post-27224","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-health","tag-astrazeneca-plc-adr-nyseazn","tag-jpmorgan-chase-co-nysejpm","tag-nyseazn","tag-nysejpm","tag-nysepfe","tag-pfizer-inc-nysepfe","entry"],"acf":[],"yoast_head":"\n